TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04778683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
Study: NCT01962415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Oral administration at 30 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Oral administration at 30 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.~Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 30 mg); Stratum 3: No treatment dose, test dose only.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: IV administration at 70 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: IV administration at 70 mg/m2/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: IV administration at 200 mg/m2/dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: IV administration at 200 mg/m2/dose
Study: NCT01107353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine Pamoate
Description: 75 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine Pamoate
Description: 75 mg capsule
Study: NCT02024399

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Strength training, aerobic exercise and core strengthening, running
Study: NCT00462202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulodexide
Study: NCT02843542

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-MR
Description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
Study: NCT04385628

Intervention type: BEHAVIORAL
Intervention: the patient' relatives satisfaction questionnaire
Description: The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
Study: NCT04563871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg Osimertinib
Description: One tablet of 80mg Osimertinib for oral administration per day
Study: NCT03551769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tricaprilin
Description: Tricaprilin formulated as AC-SD-01
Study: NCT01849146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT02667418

Intervention type: DRUG
Group type: OTHER
Intervention: Fidaxomicin
Description: 200 mg PO twice daily for 10 days
Study: NCT04330261

Intervention type: OTHER
Intervention: Exposure (not intervention) - SARS-CoV-2 infection
Description: Exposure is infection with the virus. There is no intervention
Study: NCT02667418

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin with Taper/Pulse
Description: 125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
Study: NCT04127019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy (injection)
Study: NCT03551769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tricaprilin
Description: Tricaprilin formulated as AC-SD-01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tricaprilin
Description: Tricaprilin formulated as AC-SD-01
Study: NCT04127019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)
Study: NCT04127019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)
Study: NCT02667418

Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin
Description: 125 mg PO for times daily for 10 days
Study: NCT04127019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin chemotherapy (injection)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil chemotherapy (injection)
Study: NCT03551769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tricaprilin
Description: Tricaprilin formulated as AC-SD-01

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard meal
Description: standard meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard meal
Description: standard meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard meal
Description: standard meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fat meal
Description: high-fat meal
Study: NCT03319719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero® Balance with integral lidocaine
Description: Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Belotero® Balance
Description: Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.
Study: NCT03551769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: overnight fast
Description: fasting for at least 9 hours
Study: NCT04615143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w). After 2 cycles of Tislelizumab and evaluation of resectability, patients will receive surgery in 6 weeks after enrollment. Patients will receive Tislelizumab for 1 year (200mg, iv, q3w, 17 cycles) in 4-6 weeks after surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Levatinib
Description: Patients receive Tislelizumab on week 1 and week 4 (200mg, iv, q3w); Lenvatinib from Day1 to Day 28 (8/12mg qd). After neoadjuvant treatment and evaluation of resectability, patients will receive surgery in 6weeks after enrollment. Patients will receive Tislelizumab combined with Lenvatinib for 1 year in 4-6 weeks after surgery.
Study: NCT04108208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4\*60 mg tablets) will be administrated orally once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen-deprivation Therapy (ADT)
Description: Participants will continue to receive ADT with gonadotrophin-releasing hormone agonists (GnRHa) who have not been surgically castrated.
Study: NCT02175394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356
Study: NCT04146493

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for Heparin-binding protein measurement
Description: Blood samples before and after given heparin

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for Heparin-binding protein measurement
Description: Blood samples before and after given heparin

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples for Heparin-binding protein measurement
Description: Blood samples before and after given heparin
Study: NCT03104049

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular taping
Description: NMT applications:~1. rhomboid major muscle~2. muscles abdominals~3. spinal muscles~4. pectoralis major muscles~5. gastrocnemius muscle~6. upper trapezius muscle~7. anterior muscles of the neck
Study: NCT03670524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Greenness as a therapeutic intervention
Description: Greenness to be used as a therapeutic intervention
Study: NCT03361748

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: : bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA02 CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR).
Study: NCT03633708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult CKD patients with SHPT by simultaneously controlling intact parathyroid hormone (iPTH), Ca, and phosphorus and has recently been approved for use in adult patients with SHPT treated with hemodialysis in both the United States and Europe
Study: NCT03374501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugardown™
Description: Test food #2: 495.0 g Sprite™ soft drink plus 2 Sugardown™ tablet consumed with 250 mL water (repeated twice) Test food #3: 495.0 g Sprite™ soft drink plus 4 Sugardown™ tablet consumed with 250 mL water (repeated twice)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soft drink
Description: Test food #1: 495.0 g Sprite™ soft drink consumed with 250 mL water (repeated twice)
Study: NCT01219764

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
Study: NCT00738790

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course of radiotherapy
Description: 5 x 5 Gy plus boost 4 Gy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiochemotherapy
Description: 28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
Study: NCT02627326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: periodontal surgery in the form of open flap debridement was done in both the groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open flap debridement
Description: periodontal surgery in the form of open flap debridement was done in both the groups
Study: NCT00683124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan and nebivolol
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.~Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
Study: NCT04287855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab by IV route - Cycle 1 : 10mg/kg on days 1, 8, 15 and 22 per 28 days cycle. After cycle 1 : 10mg/kg on days 1 and 15 per 28 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib by IV route - Cycle 1 : 20/27 mg/m² on days 1-2, 8-9, 15-16 per 28 days cycle. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide by oral route - Cycle 1-2 : 3mg on days 1 to 21 per 28 days cycle. After cycle 2 : 4mg on days 1 to 21 per 28 days cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone by oral route - Cycle 1-13 : 40/20 mg on days 1, 8, 15 and 22. Cycle 2-13 : 56mg/m² on days 1, 8, 15 per 28 days cycle. After cycle 13 : 56mg/m² on days 1 and 15 per 28 days cycle.
Study: NCT04144582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Docetaxel Monotherapy
Description: Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w
Study: NCT04366297

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous access
Description: obtaining intravascular access using a standard intravenous cannula

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraosseous access
Description: obtaining intravascular access using a ready intravenous NIO needle set
Study: NCT01319474

Intervention type: OTHER
Group type: OTHER
Intervention: Whole-leg compression ultrasound
Description: Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
Study: NCT00761670

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride and risperidone
Description: amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amisulpride and risperidone
Description: amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
Study: NCT01855243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 70/30 insulin
Study: NCT00693576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: 20 mg simvastatin daily
Study: NCT00384059

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: Single 0.5 mL dose given at 2, 3, 4, and 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7vPnC
Description: Single 0.5 mL dose given at 2, 3, 4 and 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediacel
Description: concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediacel
Description: concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeisVac-C
Description: concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C
Description: concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menitorix
Description: concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menitorix
Description: concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
Study: NCT03146039

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: Whole pelvis radiation therapy will be delivered according to institutional standard of care.~SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning.
Study: NCT02978001

Intervention type: OTHER
Intervention: Stabile Isotope tracers
Description: Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp

Intervention type: OTHER
Intervention: Stabile Isotope tracers
Description: Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
Study: NCT04002804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells Vaccine
Description: Right after the surgical resection of the recurrent tumor, leukapheresis will be performed.~At least 5x109 PBMC must be collected by leukapheresis, so as to make the whole immunotherapy schedule workable.~Starting at week 3, immunotherapy will include 4 bi-weeekly vaccinations first (injections I, II, III, IV), two further monthly vaccinations (injections V, VI) and a final vaccination (injection VII) two months after the sixth one. Injections I, V, VI and VII will contain 10 million tumor lysate-loaded DC, while the others will be of 5 million cells only.~Vaccine doses will be injected in the forearm of the patient.
Study: NCT04794101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Intermediate Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Intermediate Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Low Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genetic: AAV5-hRKp.RPGR Low Dose
Description: Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Study: NCT01855243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glulisine
Study: NCT02938988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy
Description: Described in arm/group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planning
Description: Described in arm/group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planning
Description: Described in arm/group

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: red laser
Description: 658nm; 0.1W; 2229J/cm², 10s per point

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylene blue dye